TAK-438 Enters Phase II Clinical Trialsfor the Treatment of Reflux Esophagitis

23-Nov-2009 - Japan

Takeda Pharmaceutical Company Limited (announced that TAK-438, which is the drug for acid-related diseases, has entered into Phase II clinical trials for the treatment of patients with reflux esophagitis in Japan.

TAK-438, originated by Takeda, is a potassium-competitive acid blocker that suppresses gastric acid secretion by inhibiting the binding of potassium ion (K+) to H+,K+-ATPase; it is a completely different mechanism of action from conventional proton pump inhibitors (“PPIs”). It is anticipated to have a more potent inhibitory effect on gastric acid secretion, a faster onset of action, and a longer lasting effect than PPIs.

“We expect TAK-438 to have greater acid suppression which may provide better clinical efficacy than PPIs which are widely used to treat acid-related diseases,” said Nancy Joseph-Ridge, M.D., General Manager, Pharmaceutical Development Division of Takeda. “We will continue the development of TAK-438 so that we might be able to offer it to patients as an optimal treatment option for the acid-related diseases, including reflux esophagitis, as quickly as possible.”

Other news from the department research and development

More news from our other portals

So close that even
molecules turn red...

Last viewed contents